➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
McKesson
Colorcon
Merck
Moodys

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Vadadustat


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Vadadustat?

Vadadustat is an investigational drug.

There have been 24 clinical trials for Vadadustat. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are Akebia Therapeutics, Mitsubishi Tanabe Pharma Corporation, and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).

There are thirteen US patents protecting this investigational drug and one hundred and twenty-four international patents.

Recent Clinical Trials for Vadadustat
TitleSponsorPhase
Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of VadadustatAkebia TherapeuticsPhase 1
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Phase 3
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)Akebia TherapeuticsPhase 3

See all Vadadustat clinical trials

Clinical Trial Summary for Vadadustat

Top disease conditions for Vadadustat
Top clinical trial sponsors for Vadadustat

See all Vadadustat clinical trials

US Patents for Vadadustat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vadadustat   Start Trial Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Akebia Therapeutics, Inc. (Cambridge, MA)   Start Trial
Vadadustat   Start Trial Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Akebia Therapeutics, Inc. (Cambridge, MA)   Start Trial
Vadadustat   Start Trial Prolyl hydroxylase inhibitors and methods of use Warner Chilcott Company, LLC (Pajardo, PR)   Start Trial
Vadadustat   Start Trial Prolyl hydroxylase inhibitors and methods of use Akebia Therapeutics Inc. (Cincinnati, OH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vadadustat

Drugname Country Document Number Estimated Expiration Related US Patent
Vadadustat Argentina 099354 2033-11-15   Start Trial
Vadadustat Australia 2014348523 2033-11-15   Start Trial
Vadadustat Australia 2019202144 2033-11-15   Start Trial
Vadadustat Brazil 112016011065 2033-11-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKinsey
Johnson and Johnson
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.